Panos G Z, Betsi G I, Falagas M E
Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece.
Aliment Pharmacol Ther. 2006 Sep 1;24(5):731-42. doi: 10.1111/j.1365-2036.2006.03036.x.
Escherichia coli O157:H7 is a foodborne pathogen causing haemorrhagic colitis, which is sometimes complicated by haemolytic uraemic syndrome or thrombotic thrombocytopenic purpura.
To review the available evidence regarding the question of whether antibiotics are effective or harmful for the treatment of patients infected with E. coli O157:H7 infection.
We searched in the PubMed for relevant laboratory and clinical studies published between 1982 and 2005.
In vitro studies have shown that most E. coli O157:H7 isolates are susceptible to various antibiotics, although certain antibiotics, especially at sublethal concentrations, have been found to increase the release of Shiga-like toxins, which have been associated with the development of haemolytic uraemic syndrome/thrombotic thrombocytopenic purpura in humans. No clinical studies have indicated that antibiotics are effective in reducing the duration of E. coli O157:H7 infection or the duration of diarrhoea or bloody diarrhoea specifically, while a few studies have supported that some antibiotics, especially quinolones and fosfomycin, may prevent the development of haemolytic uraemic syndrome or thrombotic thrombocytopenic purpura. On the other hand, there are some clinical studies that associate antibiotics with a higher risk for haemolytic uraemic syndrome and/or longer duration of diarrhoea, even with high mortality.
More randomized controlled trials are necessary in order to elucidate whether antibiotics are effective in reducing the morbidity and mortality of E. coli O157:H7 infection, rather than having a detrimental effect.
大肠杆菌O157:H7是一种食源性病原体,可引起出血性结肠炎,有时会并发溶血尿毒综合征或血栓性血小板减少性紫癜。
综述关于抗生素治疗大肠杆菌O157:H7感染患者是否有效或有害这一问题的现有证据。
我们在PubMed中检索了1982年至2005年间发表的相关实验室和临床研究。
体外研究表明,大多数大肠杆菌O157:H7分离株对各种抗生素敏感,尽管已发现某些抗生素,尤其是在亚致死浓度下,会增加志贺样毒素的释放,而志贺样毒素与人类溶血尿毒综合征/血栓性血小板减少性紫癜的发生有关。没有临床研究表明抗生素能有效缩短大肠杆菌O157:H7感染的病程或腹泻或血性腹泻的病程,而一些研究支持某些抗生素,尤其是喹诺酮类和磷霉素,可能预防溶血尿毒综合征或血栓性血小板减少性紫癜的发生。另一方面,有一些临床研究将抗生素与溶血尿毒综合征的较高风险和/或较长的腹泻病程相关联,甚至与高死亡率相关联。
需要更多的随机对照试验来阐明抗生素是否能有效降低大肠杆菌O157:H7感染的发病率和死亡率,而不是产生有害影响。